(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi (NASDAQ:SNY) Q3 2024 Earnings Call Transcript ... With sales of a EUR172 million ALTUVIIIO further established its ...

French pharmaceutical group Sanofi experienced a profitability boom in the third ... They were driven by new pharmaceutical launches (up 67.1% to €727 million), including Altuviiio, used to treat ...

With sales of a EUR172 million ALTUVIIIO further established its position ... This transaction marks an important strategic step for Sanofi to become a pure-play and science-focused biopharma ...

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia drug ...

Sanofi confirmed its full-year sales target for Dupixent of roughly 13 billion euros. Elsewhere, new pharma launches grew 67.1% to 727 million euros ($787), with hemophilia med Altuviiio ...